

# ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY

Sara Khan<sup>1,2</sup>, Palma Solano-Paez<sup>3,4</sup>, Tannu Suwal<sup>3,5</sup>, Salma Al-Karmi<sup>3</sup>, Mei Lu<sup>1</sup>, Ben Ho<sup>1</sup>, Maryam Fouladi<sup>6</sup>, Sarah Leary<sup>7</sup>, Jean M. Mulcahy Levy<sup>8</sup>, Alvaro Lassaletta<sup>9</sup>, Eloy Rivas<sup>10</sup>, Alyssa Reddy<sup>11</sup>, G. Yancey Gillespie<sup>12</sup>, Nalin Gupta<sup>13</sup>, Michael Yalon-Oren<sup>14</sup>, Laura Amariglio<sup>14</sup>, Hideo Nakamura<sup>15</sup>, Kuo-Sheng Wu<sup>16</sup>, Tai-Tong Wong<sup>16</sup>, Young-Shin Ra<sup>17</sup>, Milena La Spina<sup>18</sup>, Policlinico Vittorio Emanuele<sup>18</sup>, Luca Massimi<sup>19</sup>, Anna Maria Buccoliero<sup>20</sup>, Jordan R Hansford<sup>21</sup>, Richard G Grundy<sup>22</sup>, Dariusz Adamek<sup>23</sup>, Jason Fangusaro<sup>24</sup>, David Scharnhorst<sup>25</sup>, Donna Johnston<sup>26</sup>, Lucie Lafay-Cousin<sup>27</sup>, Sandra Camelo-Piragua<sup>28</sup>, Nabil Kabbara<sup>29</sup>, Amar Gajjar<sup>30</sup>, Mahjoub Boutarouch<sup>31</sup>, Maria Joao Gil da Costa<sup>32</sup>, Derek Hanson<sup>33,34</sup>, Paul Wood<sup>35</sup>, Maysa Al-Hussaini<sup>36</sup>, Nisreen Amayiri<sup>36</sup>, Yin Wang<sup>37</sup>, Daniel Catchpoole<sup>38</sup>, Jean Michaud<sup>39</sup>, Anne E. Bendel<sup>40</sup>, Benjamin Ellezam<sup>41</sup>, Nicholas Gerber<sup>42</sup>, Ashley Plant<sup>43</sup>, Rubens Jeffery<sup>44</sup>, Christopher Dunham<sup>45</sup>, Christopher Moertel<sup>46</sup>, Andrew Walter<sup>47</sup>, David Ziegler<sup>48</sup>, Andrew Dogshun<sup>49</sup>, Nicholas Gottardo<sup>50</sup>, Ahmet Demir<sup>51</sup>, Ramya Ramanujachar<sup>52</sup>, Eric Raabe<sup>53</sup>, Shago Mary<sup>54</sup>, Peter Dirks<sup>54</sup>, Michael Taylor<sup>54</sup>, Hwang Eugene<sup>55</sup>, Holly Lindsey<sup>56</sup>, Tarik Tihan<sup>57</sup>, Jorgensen Mette<sup>58</sup>, Christine Dahl<sup>58</sup>, Sharon Low<sup>59</sup>, Amy Smith<sup>60</sup>, Lili-Naz Hazrat<sup>54</sup>, Jesse Kresak<sup>60</sup>, Somers Gino<sup>54</sup>, Enrica Tan<sup>61</sup>, Andres Morales<sup>62</sup>, Vicente Santa-Maria<sup>62</sup>, Cynthia Hawkins<sup>54</sup>, Ute Bartels<sup>63</sup>, Derek Stephens<sup>54</sup>, Sumihito Nobusawa<sup>64</sup>, Christelle Dufour<sup>65</sup>, Franck Bourdeaut<sup>66</sup>, Nicolas Andre<sup>67</sup>, Eric Bouffet<sup>63</sup>, and Annie Huang<sup>1,63</sup>; <sup>1</sup>Arthur and Sonia Labatt Brain Tumor Research Centre, Toronto, Ontario, Canada, <sup>2</sup>Hudson Institute of Medical Research, Monash University, Melbourne, Victoria, Australia, <sup>3</sup>Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada, <sup>4</sup>Department of Paediatric Oncology, Hospital Infantil Virgen del Rocío, Sevilla, Spain, <sup>5</sup>Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, <sup>6</sup>Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, <sup>7</sup>Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, WA, USA, <sup>8</sup>Department of Pediatrics, University of Colorado, Denver, Aurora, CO, USA, <sup>9</sup>Pediatric Hematology and Oncology Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, <sup>10</sup>Hospital Universitario Virgen del Rocío, Sevilla, Spain, <sup>11</sup>University of Alabama at Birmingham, Birmingham, USA, <sup>12</sup>Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, USA, <sup>13</sup>Department of Neurological Surgery, University of California, California, San Francisco, CA, USA, <sup>14</sup>Department of Pediatric Neuro-Oncology, Sheba Medical Centre, Tel HaShomer, Ramat Gan, Israel, <sup>15</sup>Department of Neurosurgery, Kumamoto University, Kumamoto, Japan, <sup>16</sup>Taipei Medical Hospital, Taipei City, Taiwan, <sup>17</sup>Department of Neurosurgery, Asan Medical Center, Seoul, Republic of Korea, <sup>18</sup>Paediatric Haematology and Oncology Division, University of Catania, Sicily, Italy, <sup>19</sup>Department of Neurosurgery, Agostino Gemelli University Hospital, Rome, Italy, <sup>20</sup>Pathology Unit Meyer Children's Hospital, Florence, Italy, <sup>21</sup>Children's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia, <sup>22</sup>Children's Brain Tumor Research Centre, Queen's Medical Centre University of Nottingham, Nottingham, United Kingdom, <sup>23</sup>Department of Pathomorphology, Jagiellonian University Medical College, Krakow, Poland, <sup>24</sup>Department of Pediatric Hematology and Oncology, Children's Healthcare of Atlanta and the Emory University School of Medicine, Atlanta, GA, USA, <sup>25</sup>Department of Pathology, Valley Children's Hospital, Madera, CA, USA, <sup>26</sup>Department of Pediatrics Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, <sup>27</sup>Department of Pediatric Oncology, Alberta Children's Hospital, Calgary, AB, Canada, <sup>28</sup>Department of Pathology, University of Michigan, Ann Arbor, MI, USA, <sup>29</sup>Division of Pediatric Hematology Oncology, Rafic Hariri University Hospital, Beirut, Lebanon, <sup>30</sup>Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA, <sup>31</sup>Department of Neurosurgery, Mohamed Vth, University, School of Medicine, Hôpital des Spécialités, ONO CHU Ibn Sina, Rabat, Morocco, <sup>32</sup>Pediatric Hematology and Oncology Division, University Hospital S, João Alameda Hernani Monteiro, Porto, Portugal, <sup>33</sup>Division of Hematology-Oncology, Steven and Alexandra Cohen Children's Medical Center, Northwell Health, New York, NY, USA, <sup>34</sup>Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA, <sup>35</sup>Monash Children's Hospital, Melbourne, VIC, Australia, <sup>36</sup>King Hussein Cancer Center, Al-Jubaila Amman, Jordan, <sup>37</sup>Department of Neuropathology Huashan Hospital Fudan University, Shanghai, China, <sup>38</sup>The Tumour Bank, Children's Cancer Research Unit, Kids Research Institute, the Children's Hospital at Westmead, NSW, Australia, <sup>39</sup>Department of Pathology and Laboratory Medicine, Children's Hospital of Eastern Ontario, Ottawa, Canada, <sup>40</sup>University of Minnesota Medical School Minneapolis, MN, USA, <sup>41</sup>Department of Pathology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada, <sup>42</sup>Department of

Oncology, University Children's Hospital, Zurich, Switzerland, <sup>43</sup>Division of Pediatric Oncology, Children's Hospital of Orange County, Orange, CA, USA, <sup>44</sup>Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA, <sup>45</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, <sup>46</sup>Pediatric Hematology-Oncology, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA, <sup>47</sup>Division of Pediatric Hematology/Oncology duPont Hospital for Children, Wilmington, DE, USA, <sup>48</sup>Children's Cancer Institute, University of New South Wales, NSW, Australia, <sup>49</sup>Department of Paediatrics, University of Otago, Christchurch, New Zealand, <sup>50</sup>Kids Cancer Centre, Telethon Kids Institute, Subiaco, WA, Australia, <sup>51</sup>Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey, <sup>52</sup>Paediatric Haematology and Oncology, Southampton Children's Hospital, South Hampton, United Kingdom, <sup>53</sup>Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Division of Pediatric Oncology, Baltimore, MD, USA, <sup>54</sup>The Hospital for Sick Children, Toronto, ON, Canada, <sup>55</sup>Department of Oncology, Children's National Medical Center, Washington, DC, USA, <sup>56</sup>Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA, <sup>57</sup>Department of Pathology, University of California, San Francisco (UCSF), San Francisco, CA, USA, <sup>58</sup>Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, <sup>59</sup>Neurology Service, Department of Pediatrics, KK Women's and Children's Hospital, Singapore, Singapore, <sup>60</sup>Orlando Regional Medical Center, Orlando, FL, USA, <sup>61</sup>Paediatric Haematology/Oncology Service, KK Women's and Children's Hospital, Singapore, Singapore, <sup>62</sup>Neuro Oncology Unit Department of Pediatric Hematology, Oncology and Stem Cell Transplantation St Joan de Déu Children's Hospital, Barcelona, Spain, <sup>63</sup>The Hospital for Sick Children, Toronto, ON, Canada, <sup>64</sup>Department of Human Pathology, Gunma University, Gunma, Japan, <sup>65</sup>Département de Cancérologie de l'Enfant et de l'Adolescent, Institut Gustave Roussy, Villejuif, Paris, France, <sup>66</sup>PSL Research University, Institut Curie Research Center, Paris, France, <sup>67</sup>APHM La Timone Hospital, Saint-Pierre, France

ETMR, an aggressive disease characterised by *C19MC* alterations, were previously categorised as various histologic diagnoses. The clinical spectrum and impact of conventional multi-modal therapy on this new WHO diagnostic category remains poorly understood as a majority of ~200 cases reported to date lack molecular confirmation. We undertook comprehensive clinico-pathologic studies of a large molecularly confirmed cohort to improve disease recognition and treatment approaches. Amongst 623 CNS-PNETs patients enrolled in the RBTC registry, 159 primary ETMRs were confirmed based on a combination of FISH (125), methylation analysis (88), SNP and RNAseq (32) analyses; 91% had *C19MC* amplification/gains/fusions, 9% lacked *C19MC* alterations but had global methylation features of ETMR NOS. ETMRs arose in young patients (median age 26 months) predominantly as localized disease (M0-72%, M2-3 -18%) at multiple locations including cerebrum (60%) cerebellum (18%), midline structures (6%); notably 10% were brainstem primaries mimicking DIPG. Uni- and multivariate analyses of clinical and treatment details of curative regimens available for 110 patients identified metastatic disease ( $p=0.002$ ), brainstem locations ( $p=0.005$ ), extent of surgery, receipt of multi-modal therapy including high dose chemotherapy and radiation ( $P<0.001$ ) as significant treatment prognosticators, while *C19MC* status, age and gender were non-significant risk factors. Analyses of events in all patients showed respective EFS at 3 and 12 months of 84%(95%CI:77-91) and 37%(95%CI:20-41) and 4yr OS of 27%(95%CI:18-37) indicating despite intensified therapies ETMR is a rapidly progressive and fatal disease. Our comprehensive data on the largest cohort of molecularly-confirmed ETMRs provides a critical framework to guide current clinical management and development of clinical trials.

## GERM CELL TUMORS

### GCT-02. THE LONG-TERM OUTCOMES AND SEQUELAE ANALYSIS OF INTRACRANIAL GERMINOMA FROM 187 PATIENTS IN THE SINGLE INSTITUTE: NECESSITY FOR THE ADAPTATION OF RADIOTHERAPY DOSE AND VOLUME

Joo Ho Lee<sup>1</sup>, Il Han Kim<sup>1</sup>, Keun-Yong Eom<sup>2</sup>, Seung Ki Kim<sup>1</sup>, Kyu-Chang Wang<sup>1</sup>, Tae Min Kim<sup>1</sup>, Dae Seog Heo<sup>1</sup>, Hyoung Jin Kang<sup>1</sup>, and Hee Young Shin<sup>1</sup>; <sup>1</sup>Seoul National University Hospital, Seoul, Republic of Korea, <sup>2</sup>Seoul National University Bundang Hospital, Seongnam, Republic of Korea

**PURPOSE:** We aimed to refine the radiotherapy (RT) volume and dose determinant for disease failures and long-term sequelae in the intracranial germinoma. **METHODS:** The main treatment for intracranial germinoma was craniospinal RT only (n=51) during 1981–1992 and RT with upfront chemotherapy (CRT) (n=152) during 1992–2015 in Seoul National Uni-